The sixth edition of the India Pharmaceutical Forum, the annual flagship event hosted by the Indian Pharmaceutical Alliance, will be focusing on patients and quality and the response to the Covid-19 pandemic sweeping the globe.
The IPF, scheduled from 24-26 February, will be hosted virtually.
The theme of this edition of the IPF is ‘Patient Centricity: New Paradigm in Quality Management’ and is centred around the various aspects that define quality management in the pharmaceutical industry in post-Covid-19 era, reinstating patient centricity as its focus.
The three-day conference will see dignitaries from the healthcare industry and subject-matter experts expressing their views through discussions.
An exclusive CEO panel discussion on ‘The Impact of Covid-19 on Pharmaceutical Industry and the way forward’ where chiefs of leading Indian pharma companies such as Cadila Healthcare, Cipla, Dr. Reddy’s, Lupin, Sun Pharma, and Torrent Pharma will deliberate on Covid-19 response by pharma companies.
The conference will commence with a keynote address by S Aparna, Secretary, Department of Pharmaceuticals, and inauguration of IPA’s Best Practices document. This will be followed by sessions on topics under quality management, including a talk on Inspection during Covid-19 and GDUFA III Negotiation by David Gaugh, Senior Vice President for Sciences and Regulatory Affairs, AAM. An update on the USFDA Quality Standard Control will be presented by Francis Godwin, Director, Office of Manufacturing Quality, Office of Compliance, USFDA.
“Covid-19 has once again reinforced the efforts of the healthcare industry towards a patient-centric approach. This year, the 6th Indian Pharmaceutical Forum will provide an engaging platform to facilitate a comprehensive discussion on the everchanging shift in quality management, led by significant voices of the industry. It will bring together relevant stakeholders from prominent organisations, leading pharma companies and regulatory bodies to discuss an action-oriented approach to operate in the future,” said Sudarshan Jain, Secretary-General, IPA.
“The Indian pharmaceutical industry effectively rose to the challenges of Covid-19 and reinstated its potential in the global pharma landscape. Maintaining benchmark quality standards is pivotal for all IPA member companies,” said Satish Reddy, President IPA.
The forum will also encompass five panel discussions on contemporary subjects such as new paradigm in quality management, digitisation/automation, and AI in operations and more.
This article was originally published on Deccan Herald
